A Phase I Study of ABT 510 for Newly Diagnosed Glioblastoma Multiforme
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
To determine the maximum tolerated dose of ABT 510 when administered concurrent with
radiation therapy for patients with newly diagnosed glioblastoma multiforme.